David D. Chang
Co-Founder & DirectorDr. David D. Chang, M.D., Ph.D., is Co-Founder of Allogene Therapeutics, Inc. and serves as a Director since June 2018. At the company, he also served as President and Chief Executive Officer from June 2018 to June 30, 2026. He serves as Director at Peloton Therapeutics, Inc. since March 22, 2018, as Board Chairman of the Board at IconOVir Bio, Inc. since June 2020, as a Venture Partner at Two River Group Holdings, LLC, as Scientific Advisor at Vida Ventures Advisors, LLC, as a Director at A2 Biotherapeutics, as director of 1200 Pharma LLC since June 2021, and as a Member of the CalTech Cheng Medical Engineering Advisory Council. He served as a Director at Notch Therapeutics, Inc. from November 2019 to March 2022. He served as a Scientific Advisory Board Member of Kronos Bio, Inc. until February 2022. He served as Executive VP of Research & Development and Chief Medical Officer at Kite Pharma, Inc., where he was employed from June 02, 2014 to October 02, 2017. He served as Vice President of Global Oncology Development at Amgen Inc. from July 2006 to May 2014. He joined the firm on August 04, 2005. Prior to that, he held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He also served as a Director at IconOVir Bio, Inc. He has an industry-leading track record of innovation in the field of oncology drug development, including the development for Yescarta™ (axicabtagene ciloleucel), Blincyto® (blinatumomab), and IMLYGIC™ (talimogene laherparepvec). He obtained a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and a Ph.D. from Stanford University. He completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School.
Positions
- Company NameAllogene Therapeutics, Inc.Stock CodeALLOPositionCo-Founder & Director
